share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Schuyler Kevin

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Adial Pharmaceuticals | 4：持股變動聲明
美股SEC公告 ·  03/28 06:10
牛牛AI助理已提取核心訊息
In a recent transaction dated 03/25/2024, Schuyler Kevin engaged in a stock market activity involving Adial Pharmaceuticals, Inc. (ADIL). The specific details of the transaction, including the number of shares traded, the nature of the shares, the transaction price, and the resulting total value of shares held by Schuyler Kevin after the action, have not been disclosed. The relationship of Schuyler Kevin to the issuer, Adial Pharmaceuticals, was not specified in the announcement.
In a recent transaction dated 03/25/2024, Schuyler Kevin engaged in a stock market activity involving Adial Pharmaceuticals, Inc. (ADIL). The specific details of the transaction, including the number of shares traded, the nature of the shares, the transaction price, and the resulting total value of shares held by Schuyler Kevin after the action, have not been disclosed. The relationship of Schuyler Kevin to the issuer, Adial Pharmaceuticals, was not specified in the announcement.
在最近於2024年3月25日的一筆交易中，舒勒·凱文參與了涉及阿迪爾製藥公司（ADIL）的股票市場活動。該交易的具體細節，包括交易的股票數量、股票的性質、交易價格以及舒勒·凱文在訴訟後持有的股票的總價值，尚未披露。公告中沒有具體說明舒勒·凱文與發行人阿迪亞爾製藥的關係。
在最近於2024年3月25日的一筆交易中，舒勒·凱文參與了涉及阿迪爾製藥公司（ADIL）的股票市場活動。該交易的具體細節，包括交易的股票數量、股票的性質、交易價格以及舒勒·凱文在訴訟後持有的股票的總價值，尚未披露。公告中沒有具體說明舒勒·凱文與發行人阿迪亞爾製藥的關係。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。